Policy/Access

Contemplating how the pandemic may change the regulatory landscape? Our perspectives may help.

RESOURCES

We finally have a vaccine, but will this bring about a return to normality?

With unprecedented speed, the UK has become the first country to approve emergency use authorization for a COVID-19 vaccine that has been tested in a large-scale clinical trial.1 While this is a welcome milestone, it is important to remember that, as the vaccine is rolled out to millions of people, scientists and the public still […]

View

Understanding people’s fears and concerns relating to COVID-19 vaccines

Nowadays it is common practice to dismiss and even condemn people when their beliefs do not align with ours. When news began to circulate that ‘up to a third of people’ in the UK may refuse a coronavirus vaccine, based on a YouGov report of 1,663 adults, it was easy to blame this on anti-vaxxers. […]

View

How communication will be key to ensuring COVID-19 vaccine uptake

On 2nd December, the UK became the first country in the world to approve the Pfizer/BioNTech COVID-19 vaccine, following review by the MHRA. This announcement comes a ground-breaking seven months after the start of clinical trials and marks a major breakthrough, but it’s clear that the COVID-19 pandemic is far from over. Recent criticism that […]

View

Is the world ready for a COVID-19 vaccine?

At the beginning of the coronavirus pandemic, Dr Tedros Adhanom Ghebreyesus, Director General of the World Health Organization (WHO), dramatically told a G20 Leaders’ Summit that “we are at war with a virus that threatens to tear us apart.” At the same meeting, António Guterres, UN General Secretary, said “we are at war with a […]

View

The massive impact of COVID-19 on US health care

As COVID-19 continues to spread across the U.S., its impact on the U.S. health system is without precedent, with direct and indirect medical costs estimated to be in the hundreds of billions of dollars. On an individual basis, cost estimates from the Peterson Center on Healthcare and Kaiser Family Foundation (KFF) range from between $10,000 to […]

View

COVID-19 is threatening the progress of clinical trials

The financial impact of the COVID-19 pandemic presents a potential risk to the future of clinical trials in rare diseases. Rare diseases by their nature are not very prevalent in the population, therefore, any treatment for a rare disease will only have a small number of beneficiaries. In addition, so-called orphan drug development takes around 18% […]

View

Assessing and managing issues around clinical trials: a multi-stakeholder approach

Many companies are facing challenging decisions on whether to proceed with clinical trials in the coming months as countries experience varying degrees of lockdown.

View

COVID-19 has caused enforced digitalization of clinical practice – but how much will stick?

We have seen a digital revolution sweep across clinical practice, driven by the extraordinary circumstances of the coronavirus.

View

Telehealth comes to the forefront

Telehealth, in particular, has been waiting for its moment. In the U.S., the first recorded instance of telemedicine happened more than 60 years ago (!) when the Nebraska Psychiatry Institute began using closed-circuit TV for psychiatric consultations.

View

Unlocking virtual medical congresses

Medical congresses – crucial for the presentation of trial data, scientific exchange and the opportunity to engage with medical professionals, patient advocates, media and analysts – have been cancelled, postponed or are moving to virtual/part virtual.

View

No two virtual congresses are the same

Each congress has a different structure to its overall program and method in delivering its scientific information, despite stating that they all plan to keep to the traditional congress format.

Download PDF

Get in Touch

We know there are numerous considerations when it comes to the impact of COVID-19 and what this means for your organization. We are here to help.